Biosimilar
Biosimilars, or follow-on biologics, are the terms used to describe officially approved new versions of existing biopharmaceuticals whose patents have expired
All -   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z   
ADCC (Antibody-dependent cell mediated cytotoxicity)

An immune response in which antibodies, by coating target cells, make them vulnerable to attack by cells of the immune system which then may destroy the target cell. This effect appears to be an important factor in the efficacy of some monoclonal antibodies used in tumour therapy.

Aggregates
Dimeric and higher multiple forms of a desired product, e.g. a → protein. These are generally resolved from the desired product and product-related substances, and quantitated by appropriate analytical procedures (e.g., by size exclusion chromatography, → capillary electrophoresis). (ICH Q6B, http://www.ich.org/LOB/media/MEDIA432.pdf ).
Albumin
see → HSA (human serum albumin).
Antibody

A spectrum of → proteins of the immunoglobulin family that is produced, in the human (or animal) body, in response to an → antigen (e.g., a virus or bacterium, or a foreign protein unknown to the body’s immune system). Antibodies are able to combine with and neutralize the antigen, as well as to stimulate the immune system for defense reactions. (http://www.biology-online.org/dictionary/Antibody )

Antigen
A substance that reacts with the products of a specific immune response. Antigens are not necessarily → immunogens: there are small molecules (called “haptens”) which are non-immunogenic - i.e., they would not
induce an immune response when administered by themselves, but will do it when coupled to a carrier molecule. Free haptens, however, can react with products of this immune response. Thus, haptens have
the property of antigenicity but not immunogenicity.
(Modified from: http://pathmicro.med.sc.edu/mayer/antigens2000.htm )
BIOSIMILAR SELANJUTNYA >>
Medicines
About Medicines
Drug Discovery
Clinical Trials
New Therapy
Biosimilar
Diseases
IPR
» Hainan Province, Hengda Health and Korean Yuanchen Signs Strategic Cooperation Agreement
Boao, China - In the evening on March 29, Hong Kong listed company New Media (HK.708) (to be changed into Hengda Health Industry Co., Ltd.) announced that it has signed a strategic investment cooperation framework agreement with the Management Committee of the pioneer district of the international medical tourism in Lecheng, Boao, Hainan Province; and Korean Yuanchen Medical Cosmetology Group on March 28 to establish an international medical cosmetology and anti-aging center at the above mentioned pioneer district. An original report from Sina Leju follows.

More » 
Counterfeit
» BPOM seizes Rp 150 m worth of fake drugs distributed online
The National Drug and Food Monitoring Agency (BPOM), in conducting its fifth Pangea Operation, has seized thousands of illegal and fake drugs marketed online.

BPOM chairwoman Lucky S.Slamet said Monday that during the operation, her agency had identified 83 websites that allegedly distributed illegal and fake drugs, up from the 30 sites it uncovered during the previous Pangea Operation in 2011. Read full article here .
More » 
September 2017
SuMTuWThFSa
12
3456789
10111213141516
17181920212223
24252627282930

Copyright © 2013 International Pharmaceutical Manufacturers Group